Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Mar 8, 2017
Insider Transaction Report
Form 4
Lichtlen Peter
Chief Medical Officer
Transactions
- Award
Common stock
2017-03-06+24,000→ 24,000 total - Award
Employee Stock Option (right to buy)
2017-03-06+45,000→ 314,400 totalExercise: $11.85Exp: 2027-03-02→ Class A Common Stock (45,000 underlying)
Footnotes (2)
- [F1]Common stock granted consists of restricted stock units that vest on March 2, 2020.
- [F2]The option will vest over a four-year period, with 25% vesting on March 2, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter.